[HTML][HTML] Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer
L Yang, HJ **e, YY Li, X Wang, XX Liu… - Oncology …, 2022 - spandidos-publications.com
Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps
BRCA1/2 mutant tumor cells display an elevated mutation burden, the etiology of which
remains unclear. Here, we report that these cells accumulate ssDNA gaps and spontaneous …
remains unclear. Here, we report that these cells accumulate ssDNA gaps and spontaneous …
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1
immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates PARP …
immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates PARP …
Targeting DNA repair in cancer: beyond PARP inhibitors
Germline aberrations in critical DNA-repair and DNA damage–response (DDR) genes
cause cancer predisposition, whereas various tumors harbor somatic mutations causing …
cause cancer predisposition, whereas various tumors harbor somatic mutations causing …
PARP inhibitors: enhancing efficacy through rational combinations
D Bhamidipati, JI Haro-Silerio, TA Yap… - British journal of cancer, 2023 - nature.com
Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Homologous recombination (HR) repair deficiency impairs the proper maintenance of
genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair …
genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair …
Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies
A Lee, MBA Djamgoz - Cancer treatment reviews, 2018 - Elsevier
Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer
which lacks oestrogen receptors, progesterone receptors and HER2 amplification, thereby …
which lacks oestrogen receptors, progesterone receptors and HER2 amplification, thereby …